The first Phase 2 study demonstrated clinically significant results in a randomized, outpatient, placebo-controlled study at nine U.S. headache centers.
In addition, a second Phase 2 clinical trial indicated that Tempo Migraine was well tolerated by subjects with impaired pulmonary function.
Tempo™ is a proprietary orally inhaled formulation of dihydroergotamine (DHE) for the treatment of acute migraine, designed to provide faster and more consistent relief than current therapeutics.
Find more details of the clinical data from the press release.
Comment Preview